Lincluden Management Ltd. Has $10.24 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Lincluden Management Ltd. reduced its holdings in Pfizer Inc. (NYSE:PFE) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 385,837 shares of the biopharmaceutical company’s stock after selling 1,271 shares during the quarter. Pfizer accounts for about 1.2% of Lincluden Management Ltd.’s investment portfolio, making the stock its 20th largest holding. Lincluden Management Ltd.’s holdings in Pfizer were worth $10,236,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of PFE. Swedbank AB lifted its position in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after acquiring an additional 37,636 shares in the last quarter. Allworth Financial LP boosted its position in shares of Pfizer by 4.4% during the third quarter. Allworth Financial LP now owns 117,755 shares of the biopharmaceutical company’s stock worth $3,408,000 after buying an additional 4,915 shares during the period. GHP Investment Advisors Inc. grew its holdings in shares of Pfizer by 8.8% during the third quarter. GHP Investment Advisors Inc. now owns 13,697 shares of the biopharmaceutical company’s stock worth $396,000 after buying an additional 1,108 shares in the last quarter. First Financial Bankshares Inc raised its position in Pfizer by 0.3% in the 3rd quarter. First Financial Bankshares Inc now owns 412,169 shares of the biopharmaceutical company’s stock valued at $11,928,000 after buying an additional 1,334 shares during the last quarter. Finally, FCG Investment Co raised its position in Pfizer by 25.5% in the 3rd quarter. FCG Investment Co now owns 18,571 shares of the biopharmaceutical company’s stock valued at $537,000 after buying an additional 3,768 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.4 %

Shares of Pfizer stock opened at $26.67 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a fifty day simple moving average of $26.33 and a two-hundred day simple moving average of $27.38. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market capitalization of $151.14 billion, a price-to-earnings ratio of 18.92, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.45%. Pfizer’s dividend payout ratio is presently 121.99%.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PFE. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Guggenheim reiterated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Citigroup reduced their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.